Inhibrx Biosciences INBX
NASDAQ INBX
$104.70 +2.99 (+2.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2026)

Updated

Inhibrx Biosciences' Non-Current Debt was $176.29 million in Q2 2026, up 77.6% from $99.28 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2026) Analysis & Trends

At the end of FY2025, Non-Current Debt at Inhibrx Biosciences came in at $100.56 million.

  • In earlier years, Non-Current Debt was $206.97 million in FY2023.
  • The Q2 2026 figure marks the highest quarterly Non-Current Debt since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 37.34 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 62.48 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -108.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 23.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Inhibrx Biosciences 1.50 Bn 1.50 Bn - 176.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 176.29 Mn
Dec 31, 2025 100.56 Mn
Sep 30, 2025 99.92 Mn
Jun 30, 2025 99.28 Mn
Mar 31, 2025 98.65 Mn
Dec 31, 2023 206.97 Mn
API Access

Inhibrx Biosciences Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=INBX&period=max&api_key=YOUR_API_KEY